Current Affairs - International - Discussion

Japan achieved a significant medical breakthrough by approving the world’s first commercial therapies derived from induced Pluripotent Stem (iPS) cells. One treatment, called Amchepry and developed by Sumitomo Pharma, focuses on Parkinson’s disease by transplanting stem-cell precursors into the brain to replace dopamine-producing cells that are lost in patients. Another therapy named ReHeart, developed by the startup Cuorips, uses heart muscle sheets to promote the formation of new blood vessels and improve heart function in patients with heart failure. These innovations build on the Nobel Prize-winning discovery of scientist Shinya Yamanaka in 2012, and both therapies are expected to become available to patients by Summer 2026.